Characterization of global patterns and the genetics of fusidic acid resistance

Clinical Infectious Diseases

Volumn 52, Issue SUPPL. 7, 2011, Pages

  Farrell, David J ^a   Castanheira, Mariana ^a   Chopra, Ian ^b  

^a JMI LABORATORIES   (United States)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; ELONGATION FACTOR G; FUSIDIC ACID;

ARTICLE; AUSTRALIA; DRUG BINDING SITE; DRUG RESISTANCE; EUROPE; FUSA GENE; FUSB GENE; FUSC GENE; GENE; GENE MUTATION; GENETICS; HUMAN; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RIBOSOME; STAPHYLOCOCCUS INFECTION; STAPHYLOCOCCUS SAPROPHYTICUS;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DRUG RESISTANCE, BACTERIAL; FUSIDIC ACID; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; PEPTIDE ELONGATION FACTOR G; STAPHYLOCOCCUS; STAPHYLOCOCCUS SAPROPHYTICUS; WORLD HEALTH;

EID: 79955758118     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir164     Document Type: Article

References (33)

1. Dobie D, Gray J. Fusidic acid resistance in Staphylococcus aureus. Arch Dis Child 2004; 89:74-7. (Pubitemid 38122019)
2. Evans RJ, Waterworth PM. Naturally-occurring fusidic acid resistance in staphylococci and its linkage to other resistances. J Clin Pathol 1966; 19:555-60.
3. Turnidge J, Collignon P. Resistance to fusidic acid. Int J Antimicrob Agents 1999; 12(Suppl 2):S35-44. (Pubitemid 29406140)
4. Godtfredsen WO, Jahnsen S, Lorck H, Roholt K, Tybring L. Fusidic acid: a new antibiotic. Nature 1962; 193:987.
5. Arigoni D, von Daehne W, Godtfredsen WO, Melera A, Vangedal S. The stereochemistry of fusidic acid. Experientia 1964; 20:344-7.
6. Godtfredsen WO, von Daehne W, Vangedal S, Marquet A, Arigoni D, Melera A. The stereochemistry of fusidic acid. Tetrahedron 1965; 21:3505-30.
7. Yamaki H. Inhibition of protein synthesis by fusidic and helvolinic acids, steroidal antibiotics. J Antibiot (Tokyo) 1965; 18:228-32.
8. Harvey CL, Knight SG, Sih CJ. On the mode of action of fusidic acid. Biochemistry 1966; 5:3320-7.
9. Kinoshita T, Kawano G, Tanaka N. Association of fusidic acid sensitivity with G factor in a protein-synthesizing system. Biochem Biophys Res Commun 1968; 33:769-73.
10. Agirrezabala X, Frank J. Elongation in translation as a dynamic interaction among the ribosome, tRNA, and elongation factors EF-G and EF-Tu. Q Rev Biophys 2009; 42:159-200.
11. Gao YG, Selmer M, Dunham CM, Weixlbaumer A, Kelley AC, Ramakrishnan V. The structure of the ribosome with elongation factor G trapped in the posttranslocational state. Science 2009; 326: 694-9.
12. O'Neill AJ, Chopra I. Molecular basis of fusB-mediated resistance to fusidic acid in Staphylococcus aureus. Mol Microbiol 2006; 59:664-76.
13. O'Neill AJ, McLaws F, Kahlmeter G, Henriksen AS, Chopra I. Genetic basis of resistance to fusidic acid in staphylococci. Antimicrob Agents Chemother 2007; 51:1737-40. (Pubitemid 46744153)
14. Castanheira M, Watters AA, Bell JM, Turnidge JD, Jones RN. Fusidic acid resistance rates and prevalence of resistance mechanisms among Staphylococcus spp. isolated in North America and Australia, 2007-2008. Antimicrob Agents Chemother 2010; 54:3614-7.
15. Castanheira M, Watters AA, Mendes RE, Farrell DJ, Jones RN. Occurrence and molecular characterization of fusidic acid resistance mechanisms among Staphylococcus spp. from European countries (2008). J Antimicrob Chemother 2010; 65:1353-8.
16. McLaws F, Chopra I, O'Neill AJ. High prevalence of resistance to fu-sidic acid in clinical isolates of Staphylococcus epidermidis. J Antimicrob Chemother 2008; 61:1040-3. (Pubitemid 351524446)
17. Norstrom T, Lannergard J, Hughes D. Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51:4438-46. (Pubitemid 350209900)
18. Lannergard J, Norstrom T, Hughes D. Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus. Antimicrob Agents Chemother 2009; 53: 2059-65.
19. Besier S, Ludwig A, Brade V, Wichelhaus TA. Molecular analysis of fusidic acid resistance in Staphylococcus aureus. Mol Microbiol 2003; 47:463-9. (Pubitemid 36121035)
20. Laurberg M, Kristensen O, Martemyanov K, et al. Structure of a mutant EF-G reveals domain III and possibly the fusidic acid binding site. J Mol Biol 2000; 303:593-603.
21. Nagaev I, Bjorkman J, Andersson DI, Hughes D. Biological cost and compensatory evolution in fusidic acid-resistant Staphylococcus aureus. Mol Microbiol 2001; 40:433-9. (Pubitemid 32391637)
22. O'Brien FG, Price C, Grubb WB, Gustafson JE. Genetic characterization of the fusidic acid and cadmium resistance determinants of Staphylococcus aureus plasmid pUB101. J Antimicrob Chemother 2002; 50:313-21.
23. Nichols RL. Optimal treatment of complicated skin and skin structure infections. J Antimicrob Chemother 1999; 44(Suppl A):19-23. (Pubitemid 29425488)
24. Jones RN, Mendes RE, Sader Hs, Castanheira M. In vitro antimicrobial findings for fusidic acid tested against contemporary (2008-2009) gram-positive organisms collected in the United States. Clin Infect Dis 2011; 52(Suppl 7):S477-86.
25. Coutant C, Olden D, Bell J, Turnidge JD. Disk diffusion interpretive criteria for fusidic acid susceptibility testing of staphylococci by the National Committee for Clinical Laboratory Standards method. Diagn Microbiol Infect Dis 1996; 25:9-13. (Pubitemid 26349069)
26. Collignon P, Turnidge J. Fusidic acid in vitro activity. Int J Antimicrob Agents 1999; 12(Suppl 2):S45-58. (Pubitemid 29406141)
27. Skov R, Frimodt-Moeller N, Esperson F. Correlation of MIC methods and tentative interpretive criteria for disk diffusion susceptibility using NCCLS methodology for fusidic acid. Diagn Microbiol Infect Dis 2001; 40:111-6. (Pubitemid 32735548)
28. Spelman D. Fusidic acid in skin and soft tissue infections. Int J Antimicrob Agents 1999; 12(Suppl 2):S59-66.
29. O'Neill AJ, Larsen AR, Skov R, Henriksen AS, Chopra I. Characterization of the epidemic European fusidic acid-resistant impetigo clone of Staphylococcus aureus. J Clin Microbiol 2007; 45:1505-10. (Pubitemid 46762405)
30. Larsen AR, Skov RL, Jarlier V, Henriksen AS. Epidemiological differences between the UK and Ireland versus France in Staphylococcus aureus isolates resistant to fusidic acid from community-acquired skin and soft tissue infections. J Antimicrob Chemother 2008; 61:589-94. (Pubitemid 351321132)
31. Laurent F, Tristan A, Croze M, et al. Presence of the epidemic European fusidic acid-resistant impetigo clone (EEFIC) of Staphylococcus aureus in France. J Antimicrob Chemother 2009; 63:420-1.
32. Whitby M. Fusidic acid in the treatment of methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 1999; 12(Suppl 2): S67-71. (Pubitemid 29406143)
33. Chen HJ, Hung WC, Tseng SP, Tsai JC, Hsueh PR, Teng LJ. Fusidic Acid Resistance Determinants in Staphylococcus aureus Clinical Isolates. Antimicrob Agents Chemother 2010; [Epub ahead of print].